Meeting NewsVideo

VIDEO: New data emerges for immunotherapy in frontline treatment of advanced lung cancer

NEW YORK — In this video commentary from HemOnc Today New York, Taofeek K. Owonikoko, MD, PhD, discussed the existing and emerging evidence of immunotherapy for the frontline treatment of patients with advanced lung cancer.

Evidence has shown that patients with specific tumor histology, molecular profile and gene mutations may benefit from different immunotherapy agents.

Owonikoko cited several studies, including one that suggested tumor mutational burden may help select patients who may be candidates for combination immunotherapy with nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb), and another that suggested benefit for the addition of atezolizumab (Tecentriq, Genentech) to the standard backbone of carboplatin, paclitaxel and bevacizumab (Avastin, Genentech).

“We await the full results of these two studies to help us better understand the appropriate patients for these emerging regimens,” Owonikoko told HemOnc Today.

Disclosure: Owonikoko reports advisory board roles with AbbVie, AstraZeneca, Bristol-Myers Squibb, EMD Serono/Merck and Novartis, as well as research funding from AstraZeneca, Bristol-Myers Squibb, Novartis and Pfizer.

NEW YORK — In this video commentary from HemOnc Today New York, Taofeek K. Owonikoko, MD, PhD, discussed the existing and emerging evidence of immunotherapy for the frontline treatment of patients with advanced lung cancer.

Evidence has shown that patients with specific tumor histology, molecular profile and gene mutations may benefit from different immunotherapy agents.

Owonikoko cited several studies, including one that suggested tumor mutational burden may help select patients who may be candidates for combination immunotherapy with nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb), and another that suggested benefit for the addition of atezolizumab (Tecentriq, Genentech) to the standard backbone of carboplatin, paclitaxel and bevacizumab (Avastin, Genentech).

“We await the full results of these two studies to help us better understand the appropriate patients for these emerging regimens,” Owonikoko told HemOnc Today.

Disclosure: Owonikoko reports advisory board roles with AbbVie, AstraZeneca, Bristol-Myers Squibb, EMD Serono/Merck and Novartis, as well as research funding from AstraZeneca, Bristol-Myers Squibb, Novartis and Pfizer.

    See more from HemOnc Today New York